Oral Abstracts—Monday, September 24, 2018
OA02.06 A Phase II Trial of Poziotinib in EGFR and HER2 exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC)

https://doi.org/10.1016/j.jtho.2018.08.243Get rights and content
Under an Elsevier user license
open archive

Cited by (0)